Now Playing
Opinion|Videos|February 15, 2024
Testing for MRD With ctDNA in Colorectal Cancer (CRC)
A panel of medical oncologists introduce themselves and provide an overview of circulating tumor DNA (ctDNA) and how it relates to MRD (minimal residual disease) testing in colorectal cancer (CRC).
Advertisement
Episodes in this series
Advertisement
Related to this article
More than two-thirds of patients with mismatch repair–deficient locally advanced rectal cancer achieved a clinical complete response with dostarlimab alone.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
2
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
3
What Are the Top Takeaways for Neuroendocrine Carcinoma From 2026 ESMO?
4
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
5